ReVision Implant has raised €4mn in an oversubscribed funding round as it prepares to move from preclinical development into human trials for its experimental visual prosthesis technology.

The financing attracted support from existing shareholders as well as new investors, including European business leaders and medical technology executives, signalling growing confidence in the company’s approach to neurotechnology.

ReVision Implant is developing a cortical visual prosthesis intended to restore functional vision for people with severe blindness, including patients who are unable to benefit from retinal or optic nerve therapies. Rather than targeting the eye itself, the system interfaces directly with the brain’s visual cortex, bypassing damaged optical pathways.

The latest funding will support the company’s operational expansion as it prepares for clinical testing. ReVision Implant has already begun establishing its own cleanroom facilities to bring more manufacturing processes in-house and strengthen quality control ahead of regulatory studies.

The company has also received backing through several European public innovation programmes, including grants from the European Innovation Council. Additional support has come from incubator programmes run by Plug and Play and imec.

Frederik Ceyssens said the funding marked an important transition point for the business. “We are moving from development towards clinical and operational scale-up,” he said, adding that the company would continue expanding its team, manufacturing capabilities and regulatory programme.

The announcement comes amid growing momentum in neurotechnology, as advances in brain-computer interfaces improve the ability to connect electronic devices directly to neural systems. Researchers and companies in the field are increasingly targeting conditions including paralysis, speech impairment, limb loss and blindness.

ReVision Implant recently received Breakthrough Device designation from the U.S. Food and Drug Administration, a status intended to accelerate the development and review of potentially transformative medical technologies.

The company is now preparing for first-in-human studies after receiving regulatory approval for the initial phase of trials, which are scheduled to begin in the third quarter of 2026.

The funding positions ReVision Implant to take the next step in translating experimental neurotechnology into clinical applications aimed at restoring lost sensory function.